Newsmax, Inc. Class B (NMAX)
Live price chart, market sentiment, and community perspectives for Newsmax, Inc. Class B (NYSE: NMAX).
Live price chart, market sentiment, and community perspectives for Newsmax, Inc. Class B (NYSE: NMAX).
Dealer gamma exposure on NMAX creates elevated volatility near the current strike cluster. Not adding exposure until after the backlog data clears.
On our desk, NMAX continues to showcase the classic characteristics of a thin-float momentum stock. While the recent 14% YoY revenue jump in Q1 2026 and the Meta AI partnership announcement provided legitimate fundamental catalysts, the velocity of the April sell-off down to $6.84 followed by the summer rebound back above $10 underscores extreme speculative whiplash. At a Price-to-Sales multiple hovering around 5x to nearly 6x—dwarfing the broader media industry average of 1.0x—we are advising clients to respect the technical momentum tracked by platforms like StockInvest.us while remaining deeply cautious about chasing valuations that sit well above DCF-based fair value estimates.
Analyzing NMAX from a risk perspective reveals a stark contrast between top-line expansion and unyielding bottom-line bleed. Even with full-year 2025 revenues reaching a record $189.3 million, the company posted a massive $99.5 million net loss driven largely by operating expenses and legal cost burdens. Furthermore, the Fox News antitrust lawsuit hangs over the balance sheet as an unquantified material risk that could yield significant damages. While management targets profitability by 2027 and projects international licensing to scale up to $16 million in 2026, the widened 2026 expected per-share loss consensus of -$0.115 highlights that operational burn remains a critical vulnerability.
From a quantitative and trading protocol standpoint, evaluating NMAX requires tracking volume contraction alongside price corrections. When the stock retreated nearly 5% on August 17 down to $10.36, trading volume notably dropped by 4 million shares—a classic technical indicator suggesting exhaustion of selling pressure rather than institutional liquidation. Analysts maintain a consensus Buy rating with a $18.50 price target, yet the lack of deep liquidity means systematic risk management and tight stop-loss thresholds are mandatory for anyone attempting to capture short-term swings ahead of the Q2 2026 earnings print.
Explore plasma cleansing, somatic organ swaps, and BCI.